The BiosecureAct in the US could be a game-changer for Indian CRAMs players like Divis

Discussion in 'Latest Brokerage Stock Buy-Sell Reports' started by Vidhi Khanna, Aug 27, 2024.

  1. Vidhi Khanna

    Vidhi Khanna Active Member Staff Member

    Joined:
    Mar 19, 2015
    Messages:
    757
    Likes Received:
    55
    ICICID says the US' Biosecure Act which seeks to restrict Chinese biotech cos operating in the US could provide a significant opportunity for Indian CRAMs players like Divis, Syngene. CRAMs industry is $7B & growing at 14% CAGR. Biosecure Act could further accelerate this growth https://twitter.com/ICICI_Direct/status/1828435544512074023

    [​IMG]
     
Loading...